Association of Timely Spirometry With Lower All-Cause Mortality
CHEST · 2025-09 · 168 (3) · 602-612
DOI: 10.1016/j.chest.2025.03.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift CHEST, 2025-09. Verfasst von Valerie Dehondt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioanalysis, Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Spirometry, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universiteit Gent.
Abstract (Originalsprache)
BACKGROUND: Although spirometry is the gold standard for diagnosing COPD, it is underused in clinical practice. RESEARCH QUESTION: Which factors are associated with timely spirometry (at chronic treatment initiation) in a clinically relevant population of people starting chronic treatment for respiratory symptoms? Is this diagnostic test associated with lower mortality risk? STUDY DESIGN AND METHODS: Incident adult users of chronic respiratory medication were identified in Belgian nationwide data. The odds on timely spirometry were examined by multivariable logistic regression and impact on survival by using multivariable Cox regression analysis. In those patients not receiving timely spirometry, factors related to further delay in spirometry were analyzed with a multivariable Fine-Gray subdistribution hazard regression. RESULTS: Among 146,205 chronic treatment initiators, 20.9% had spirometry at treatment initiation, and 13.8% received spirometry during follow-up. Although primary care physicians prescribed 81.1% of initiated treatments, general practitioners performed only 5.1% of all spirometry tests. People who received spirometry at treatment initiation had a 34% lower mortality risk (adjusted hazard ratio, 0.66; 95% CI, 0.63-0.70) and had less use of short-acting bronchodilators. Smoking, respiratory morbidities, and congestive heart failure increased chance of spirometry use. In contrast, female sex, age 80 years, cognitive impairment, and frailty lowered the chance of spirometry use, both at initiation and during follow-up. Low socioeconomic status, depression/anxiety, and antibiotic use were associated with a lower chance of spirometry use at treatment initiation, whereas during follow-up, antibiotic use was associated with a higher chance of spirometry over time. In addition, anemia and cachexia were associated with a lower chance of spirometry use during follow-up. INTERPRETATION: Only 1 in 3 initiators of chronic treatment for obstructive lung disease underwent spirometry. Spirometry was particularly underused in primary care. Especially (never-smoking) female participants and vulnerable patients may be at increased risk for underdiagnosis and suboptimal treatment. Importantly, spirometry at treatment initiation was significantly associated with better prognosis, possibly through better-tailored care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Bioanalysis, Ghent University, Ghent, Belgium.
- Department of Respiratory Medicine, Ghent University, Ghent, Belgium.
- Department of Bioanalysis, Ghent University, Ghent, Belgium; Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: Lies.Lahousse@UGent.be.
Förderung
- Universiteit Gent
Zitieren
APA
Dehondt, V., Vauterin, D., Derom, E., & Lahousse, L. (2025). Association of Timely Spirometry With Lower All-Cause Mortality. CHEST, 168(3), 602-612. https://doi.org/10.1016/j.chest.2025.03.018
Vancouver
Dehondt V, Vauterin D, Derom E, Lahousse L. Association of Timely Spirometry With Lower All-Cause Mortality. CHEST. 2025;168(3):602-612. doi:10.1016/j.chest.2025.03.018
BibTeX
@article{Dehondt2025,
author = {Dehondt, Valerie and Vauterin, Delphine and Derom, Eric and Lahousse, Lies},
title = {Association of Timely Spirometry With Lower All-Cause Mortality},
journal = {CHEST},
year = {2025},
volume = {168},
number = {3},
pages = {602--612},
doi = {10.1016/j.chest.2025.03.018}
}
EUVIMED